DGAP-News: WaveLight AG: Sale of Intraocular Surgery Business Unit Completed


WaveLight AG / Disposal


Release of a Corporate-announcement, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

WaveLight AG: Sale of Intraocular Surgery Business Unit Completed

Dutch company Procornea Holding B.V. acquires equity interests

Erlangen, December 17, 2007. WaveLight AG, which is listed in Deutsche
Börse AG’s Prime Standard, announced today that as part of its strategic
and operational realignment, the Erlangen-based medical technology company
has disposed of its Intraocular Surgery Business Unit.

Following the resolution on the sale by WaveLight AG’s Executive Committee
on December 6, 2007, the wholly owned Berlin-based WaveLight GmbH and
WaveLight AG’s 30 percent equity interest in the Dutch company MDP B.V.
will be sold to Dutch company Procornea Holding B.V. with effect from
December 14, 2007.

The parties have agreed that the purchase price and further transaction
details shall remain confidential. WaveLight expects the sale of the equity
interests to result in extraordinary expenses of up to EUR 5 million.

Procornea Holding B.V., domiciled in Eerbeek, the Netherlands, was founded
in 1975 and is a specialist in the development and production of
intraocular lenses and contact lenses. The acquisition of the equity
interests in WaveLight GmbH and MDP B.V. will boost Procornea’s development
and sales expertise in the field of intraocular surgery.

'The sale of the WaveLight’s Intraocular Surgery Business Unit is an
important step in the Group’s strategic and operational realignment. Going
forward, we will concentrate fully on the Company’s core competency in the
field of laser systems for refractive surgery and will continue to drive
forward global market penetration,' said Max Reindl, CEO of WaveLight AG,
commenting on the completion of the transaction.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG, listed in Deutsche Börse AG’s Prime Standard since January
2003, develops, produces, and markets a high-quality, end-to-end product
portfolio in the field of ophthalmology, and is a specialist for optical
technology. WaveLight's global market success is based on its innovative
range of products that are the technology leaders in their areas of
application and its broad-based sales network featuring both own
subsidiaries and strategic partners.

Further information on WaveLight is available at: www.wavelight.com

Press Contacts:

Susanne Grethlein   Gerhard Lodzwik

WaveLight AG    AGIL Gesellschaft für                                 
Finanzkommunikation mbH

Tel: + 49/9131/6186-103   Tel: +49/2131/12 55 73

Fax: +49/9131/6186-112   Fax: +49/2131/12 557 55

E-mail: susanne.grethlein@wavelight.com E-mail: info@AGIL-IR.com


Some of the statements made in this disclosure take the form of forecasts
or could be interpreted as such. All information is given and all
assessments are made on the basis of extremely conscientious research.
However, no guarantee is given with regard to the information or
assessments published. No liability whatsoever is accepted. The above
statements do not represent an invitation to buy or sell securities. All
rights reserved.
DGAP 17.12.2007 
Language:     English
Issuer:       WaveLight AG
              Am Wolfsmantel 5
              91058 Erlangen
Phone:        +49 (0)9131 - 61 86-0
Fax:          +49 (0)9131 - 61 86-111
E-mail:       info@wavelight.com
Internet:     www.wavelight.com
ISIN:         DE0005125603
WKN:          512560
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service